Cargando…
Respirable antisense oligonucleotides: a new drug class for respiratory disease
Respirable antisense oligonucleotides (RASONs), which attenuate specific disease-associated mRNAs, represent a new class of respiratory therapeutics with considerable potential. RASONs overcome previous obstacles that have impeded the development of antisense therapeutics targeting diseases in other...
Autores principales: | Tanaka, Makoto, Nyce, Jonathan W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59563/ https://www.ncbi.nlm.nih.gov/pubmed/11686859 http://dx.doi.org/10.1186/rr32 |
Ejemplares similares
-
Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023) -
The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012) -
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
por: Gagliardi, Maria, et al.
Publicado: (2021) -
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
por: Dhuri, Karishma, et al.
Publicado: (2020) -
New treatments for myasthenia: a focus on antisense oligonucleotides
por: Angelini, Corrado, et al.
Publicado: (2013)